WMSA
AVDL

Weiss Multi-Strategy Advisers’s Avadel Pharmaceuticals AVDL Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-15,300
Closed -$250K – 385
2015
Q3 		$250K Buy
15,300
+300
+2% +$6.61K 0.01% 360
2015
Q2 		$318K Buy
+15,000
New +$269K 0.01% 400

Other funds holding AVDL

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
FPC
Falcon Point Capital San Francisco, California $11.9M AUM 55.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Weiss Multi-Strategy Advisers's AVDL Position: Q1 2016 in Review

Weiss Multi-Strategy Advisers sold out of Avadel Pharmaceuticals (AVDL) in Q1 2016, closing a stake of 26,000 shares — an estimated $317K sold.

Weiss Multi-Strategy Advisers first reported a position in AVDL in Q1 2014 and held it in 8 quarters. The position peaked at $4.63M in Q4 2014. 81 funds tracked by Wall St. Rank hold AVDL as of Q1 2016.

  • Weiss Multi-Strategy Advisers reported no remaining Avadel Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Weiss Multi-Strategy Advisers sold 26,000 Avadel Pharmaceuticals shares in Q1 2016, an estimated $317K.
  • Weiss Multi-Strategy Advisers first reported a position in Avadel Pharmaceuticals in Q1 2014 and held it in 8 quarters.
  • Weiss Multi-Strategy Advisers's Avadel Pharmaceuticals position peaked at $4.63M in Q4 2014.
  • 81 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2016.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q1 2016, filed 16 May 2016.